Lexicon Pharmaceuticals (LXRX) Total Current Liabilities (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Total Current Liabilities data on file, last reported at $9.9 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $9.9 million, down 91.06% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.9 million (down 91.06% YoY), and the FY2025 annual result was $20.9 million, down 53.88% from the prior year.
• Total Current Liabilities fell to $9.9 million in Q1 2026 per LXRX's latest filing, from $20.9 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $110.7 million in Q1 2025 and troughed at $9.9 million in Q1 2026.
• A 5-year average of $30.5 million and a median of $23.4 million in 2024 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2025 and 2026: Total Current Liabilities jumped 373.07% in 2025, then slumped 91.06% in 2026.
• A 5-year view of Total Current Liabilities shows it stood at $23.2 million in 2022, then soared by 36.14% to $31.5 million in 2023, then soared by 43.43% to $45.2 million in 2024, then plunged by 53.88% to $20.9 million in 2025, then tumbled by 52.57% to $9.9 million in 2026.
• Business Quant data shows LXRX's Total Current Liabilities at $9.9 million in Q1 2026, $20.9 million in Q4 2025, and $21.7 million in Q3 2025.